Results 51 to 60 of about 5,054 (133)

Differential Gene Expression Profiling of Orbital Adipose Tissue in Thyroid Orbitopathy [PDF]

, 2015
Published under a Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode)PURPOSE. We aimed to determine differentially expressed genes relevant to orbital inflammation and orbital fat
Burdon, Kathryn Penelope, Craig, Jamie E, Ebeling, Peter R, Hardy, Thomas G, Jung, Chol-Hee, Khong, Jwu Jin, Llamas, Bastien, McNab, Alan A, Selva, Dinesh, Sharma, Shiwani, Smyth, Gordon K, Wang, Lynn Yuning   +11 more
core   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

Advanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

Miosite do músculo reto medial como forma atípica de apresentação de linfoma tipo MALT: relato de caso [PDF]

, 2014
Here we describe the rare case of a 55-year-old man with medial rectus muscle myositis as an atypical presentation of non-Hodgkin B-cell mucosa-associated lymphoma (MALT).
Dittrich, Mirtha Alicia Ramirez, Manso, Paulo Gois, Medrado, Juliana de Sá Freire, Sousa, Jacqueline Martins de, Teixeira, Luiz Fernando   +4 more
core   +4 more sources

Exploring the Therapeutic Mechanism of Xiehuo Pingtu San in Treating Thyroid Eye Disease Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Xiehuo Pingtu San (XHPTS) has been shown to be safe and effective in treating thyroid eye disease (TED), yet its underlying mechanisms remain unclear. This study aimed to elucidate the active ingredients of XHPTS and their therapeutic mechanisms in TED through network pharmacology, molecular docking, and molecular dynamics simulations ...
Ping Wang, Ruiyan Liu, Xin Shang, Yu Fu, Ying Wang, Shuxun Yan, Suraiya Saleem   +6 more
wiley   +1 more source

The influence of hepatitis C infection and interferon-α therapy on thyrotropin blocking and stimulating autoantibodies in Graves' ophthalmopathy: a case report [PDF]

, 2009
Background Hepatitis C virus is a highly immunogenic pathogen often inducing autoimmune activation changes and this can often be further exacerbated by Interferon therapy.
Huy A Tran, Glenn EM Reeves
core   +1 more source

Quantitative MRI Assessment of Orbital Structures in Radioactive Iodine‐131 Therapy for Inactive Graves’ Ophthalmopathy

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Objective The understanding regarding the role of orbital magnetic resonance imaging (MRI) in predicting the prognosis of radioactive iodine‐131 (I‐131) therapy for patients with inactive Graves’ ophthalmopathy (GO) is limited. Therefore, this study aimed to explore the application of MRI quantitative measurements of orbital structures in radioactive I‐
Man Wang, Zhong-Yuan Shen, Xing-Wang Wu, Suraiya Saleem   +3 more
wiley   +1 more source

Early Low‐Dose Rituximab for Mild‐to‐Moderate Thyroid Eye Disease: A Preliminary Evaluation of Efficacy and Safety

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Thyroid eye disease (TED) is an autoimmune inflammatory condition linked to thyroid dysfunction, which can result in disfigurement and potential vision loss. Recently, immunomodulatory therapies such as rituximab have demonstrated potential benefit in managing TED.
Ming Lu, Luqiang Wang, Xuelian Zhang, Suraiya Saleem   +3 more
wiley   +1 more source

Treatment of Graves' ophthalmopathy

Клиническая и экспериментальная тиреоидология, 2010
Graves' ophthalmopathy is one of most frequent extrathyroid manifestation of autoimmune thyroid diseases. In 3–5% cases it has severe progress and requires specific therapy.

doaj   +1 more source

Evaluation of the patients with Grave’s ophthalmopathy after the corticosteroids treatment [PDF]

Vojnosanitetski Pregled, 2012
Background/Aim. Graves’ ophthalmopthy is one of the most common causes of exophthalmos as well as the most common manifestation of Graves’ disease. The treatment of Graves’ ophthalmopathy includes ophthalmological and endocrinological therapy. The aim
Janićijević-Petrović Mirjana, Šarenac Tatjana, Srećković Sunčica, Petrović Marko, Vulović Dejan, Janićijević Katarina   +5 more
doaj   +1 more source

Selenium improves mild Graves’Orbitopathy: a randomized, double-blind, placebo-controlled study. [PDF]

, 2011
Background Free oxygen radicals and cytokines play a pathogenic role in Graves’ orbitopathy (GO). This study reports the results of a randomized, double-blind, placebo-controlled trial on the effect of selenium, an antioxidant agent, or pentoxifylline ...
ALTEA, MARIA ANTONIETTA
core